

From: [Tran, Frank](#)
To: [Le-Cun Xu](#)
Subject: Request for additional information regarding the renewal application for NRC License No. 13-32212-01
Date: Monday, March 23, 2020 5:39:00 PM
Attachments: [image001.png](#)

Dear Dr. Xu:

We have reviewed your response dated March 23, 2020. We will need the following concern be addressed.

In a response to Item 12.b, you stated the licensee will perform monthly radiation survey of the area where less than 50 microcuries of licensed material was used at a time. However, Table M-1, "Suggested Contamination Survey Frequency", in NUREG-1556, Volume 7, Revision 1, recommends that if a licensed material with quantity more than or equal to 0.1 of ALI (annual limit of intake) but less than ALI was used at any one time at any particular location, the licensee should conduct contamination survey at weekly basis. If less than 0.1 of ALI was used, the licensee could conduct monthly contamination survey.

Please provide that the licensee will implement the contamination survey frequency as listed in Table M-1 of Appendix M to NUREG-1556, Volume 7, Revision 1. Alternatively, you could provide justification for your contamination survey frequency as responded in Item 12.b in the letter dated March 23, 2020. We will review your justification case by case using the regulations in Subpart N, "Exemptions and Additional Requirements" of Title 10 of the Federal Regulations (10 CFR) part 20.

Please provide a signed and dated response by March 25, 2020. Based on the limited access to the NRC facility during this time, please email your response to frank.tran@nrc.gov (ATTN: CN 616030).

Please let me know if you have any question regarding the above.

Best regards,

Frank Tran

From: Le-Cun Xu <Le-Cun.Xu@adacap.com>
Sent: Monday, March 23, 2020 3:11 PM
To: Tran, Frank <Frank.Tran@nrc.gov>
Subject: [External_Sender] RE: Request for additional information regarding the renewal application for NRC License No. 13-32212-01

Hi Frank,

Please find the response to the request for additional information. Should you have any additional questions, please do not hesitate to contact me.

Thanks,

Le-Cun

Le-Cun Xu, Ph.D.

Radiation Safety Officer

Research Advisor

Endocyte, Inc.

Endocyte is now part of Advanced Accelerator Applications, the Radioligand business of Novartis

3000 Kent Ave., West Lafayette, IN 47906

Email: le-cun.xu@adacap.com

Phone: 765-807-0606

Cell phone: 765-337-8239

www.adacap.com

